COPD
GSK-222725
Home » Clinical Trials » COPD – GSK 222725
ELIGIBILITY & REQUIREMENTS
- Aged 40-80
- Have COPD
WHAT'S INVOLVED
- The trial will run for min 52 weeks to max 104 weeks
- 15 clinic visits to the Institute for Respiratory Health in Midland (if on 104-week trial)
- 15 Phone calls (if on 104-week trial)
- A full health check by our doctors and nurses
- Reimbursement for travel expenses
- Personalised health care with our doctors and nurses
STUDY OUTLINE
Study doctors are assessing an investigational medication — a type of biologic medicine given as shots just under the skin. They want to see if it can lower the number of moderate/ severe exacerbations (symptom flare-ups) and improve symptoms and quality of life compared to placebo when used as add-on therapy. Researchers also want to assess how safe the investigational medication is in this population. In this research study, you will get either investigational medication or placebo.
To find out if this trial is suitable for you, please register below, or contact our Clinical Trials Team on 6151 0888 or email clinicaltrials@resphealth.uwa.edu.au
PRINCIPAL INVESTIGATOR
Dr David Manners (Midland)